102 related articles for article (PubMed ID: 20010171)
1. Future novel single agent and combination therapies.
Cirstea D; Vallet S; Raje N
Cancer J; 2009; 15(6):511-8. PubMed ID: 20010171
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib: a valuable new antineoplastic strategy in multiple myeloma.
Bladé J; Cibeira MT; Rosiñol L
Acta Oncol; 2005; 44(5):440-8. PubMed ID: 16118077
[TBL] [Abstract][Full Text] [Related]
3. Moving disease biology from the lab to the clinic.
Anderson KC
Cancer; 2003 Feb; 97(3 Suppl):796-801. PubMed ID: 12548578
[TBL] [Abstract][Full Text] [Related]
4. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
5. Novel agents on the horizon for cancer therapy.
Ma WW; Adjei AA
CA Cancer J Clin; 2009; 59(2):111-37. PubMed ID: 19278961
[TBL] [Abstract][Full Text] [Related]
6. Novel therapeutic targets for multiple myeloma.
Mahindra A; Cirstea D; Raje N
Future Oncol; 2010 Mar; 6(3):407-18. PubMed ID: 20222797
[TBL] [Abstract][Full Text] [Related]
7. Evolving role of novel agents for maintenance therapy in myeloma.
Magarotto V; Palumbo A
Cancer J; 2009; 15(6):494-501. PubMed ID: 20010169
[TBL] [Abstract][Full Text] [Related]
8. New developments in the treatment of patients with multiple myeloma.
Minnema MC; van der Spek E; van de Donk NW; Lokhorst HM
Neth J Med; 2010 Jan; 68(1):24-32. PubMed ID: 20103818
[TBL] [Abstract][Full Text] [Related]
9. "Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma.
Gasparetto C; Gockerman JP; Diehl LF; de Castro CM; Moore JO; Long GD; Horwitz ME; Keogh G; Chute JP; Sullivan KM; Neuwirth R; Davis PH; Sutton LM; Anderson RD; Chao NJ; Rizzieri D
Biol Blood Marrow Transplant; 2010 Jan; 16(1):70-7. PubMed ID: 19733251
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib in the front-line treatment of multiple myeloma.
Richardson PG; Mitsiades C; Schlossman R; Ghobrial I; Hideshima T; Munshi N; Anderson KC
Expert Rev Anticancer Ther; 2008 Jul; 8(7):1053-72. PubMed ID: 18588451
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
Ludwig H; Khayat D; Giaccone G; Facon T
Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification in the era of novel therapies.
San-Miguel J; Mateos MV; Gutierrez NC
Cancer J; 2009; 15(6):457-64. PubMed ID: 20010164
[TBL] [Abstract][Full Text] [Related]
13. Treatment of multiple myeloma: an emphasis on new developments.
Kyle RA; Vincent Rajkumar S
Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibition in multiple myeloma.
Kropff M; Bisping G; Wenning D; Berdel WE; Kienast J
Eur J Cancer; 2006 Jul; 42(11):1623-39. PubMed ID: 16820291
[TBL] [Abstract][Full Text] [Related]
15. Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma.
Vogl DT; Stadtmauer EA; Richardson PG; Sonneveld P; Schuster MW; Irwin D; Facon T; Harousseau JL; Boral A; Neuwirth R; Anderson KC
Br J Haematol; 2009 Nov; 147(4):531-4. PubMed ID: 19725827
[TBL] [Abstract][Full Text] [Related]
16. Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.
de Queiroz Crusoe E; Maiso P; Fernandez-Lazaro D; San-Segundo L; Garayoa M; Garcia-Gomez A; Gutierrez NC; Delgado M; Colado E; Martin-Sanchez J; Lee FY; Ocio EM
Ann Hematol; 2012 Feb; 91(2):257-69. PubMed ID: 21720745
[TBL] [Abstract][Full Text] [Related]
17. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
18. New drugs for myeloma.
Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
[TBL] [Abstract][Full Text] [Related]
19. Management of multiple myeloma with bortezomib: experts review the data and debate the issues.
Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P
Oncology; 2006; 70(6):474-82. PubMed ID: 17283449
[TBL] [Abstract][Full Text] [Related]
20. Bortezomib and its role in the management of patients with multiple myeloma.
Orlowski RZ
Expert Rev Anticancer Ther; 2004 Apr; 4(2):171-9. PubMed ID: 15056047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
